Re-evaluating Diabetes Targets in Older Adults - Does Frailty Matter?

Introduction

The management of type 2 diabetes in older adults should be optimised with treatment plans that balance glycaemic control with the risks of hypoglycaemia and overtreatment. Overly strict glucose control has been linked to higher mortality, with inappropriate medication use contributing to dangerous hypoglycaemic episodes. NICE guidelines currently suggest an HbA1c target of ≤53 mmol/mol on a hypoglycaemic agent, with less ambitious targets for older or frail individuals to avoid risks such as hypoglycaemia and falls. This audit aims to assess glycaemic control in older adults, focusing on the prevalence of varying glycaemic levels, the relationship between HbA1C and frailty, and the medication burden in frail individuals.

Method

A registry of 57 patients aged 65 and over at Chelsea and Westminster Hospital was established, with patients stratified by frailty (Clinical Frailty Scale (CFS): mild, moderate, and severe). The average HbA1c for each group was calculated, and relationships between frailty, polypharmacy, and hypoglycaemic events were examined.

Results

Among 34 patients with available HbA1c data, 43.50% did not meet the target of ≤53 mmol/mol. The moderate frailty group (CFS 5-6) had the highest average HbA1c at 64.1 mmol/mol, with 47.06% failing to meet the target. The severe frailty group (CFS 7-9) had 66.67% meeting the target of ≤7.0%, suggesting that the current approach to glucose control may be too stringent for this group. Additionally, 55.56% of patients in this group were prescribed medications associated with higher hypoglycaemia risk.

Conclusion

In conclusion, this audit highlights the urgent need for a more nuanced approach to glycaemic control in older adults, particularly in frail populations. The findings urge us to reconsider the one-size-fits-all approach to diabetes management and explore more personalised, flexible strategies that prioritise quality of life, reduce medication burdens, and ultimately prevent complications from hypoglycaemic agents.